Jade Biosciences Inc. (AVTE)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
AVTE Chart
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.
Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The global Pulmonary Arterial Hypertension market size is expected to reach $12.2 billion by 2032. Aerovate has been able to take what was achieved with oral Imatinib and convert it to a dry inhaled powder that can be used to treat pulmonary arterial hypertension.
Jade Biosciences Inc. (AVTE) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Jade Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Timothy P. Noyes CEO | NASDAQ (NMS) Exchange | 008064107 CUSIP |
| US Country | 4 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Aerovate Therapeutics, Inc. is a progressive clinical-stage biopharmaceutical company anchored in the mission to develop pioneering drugs for patients grappling with rare cardiopulmonary conditions. Established in 2018, Aerovate is propelled by a focused vision and intricate understanding of the needs within this niche medical domain. This patient-centric approach underscores its commitment to enhancing patient outcomes and quality of life. With its strategic base in Waltham, Massachusetts, Aerovate is at the forefront of leveraging innovative approaches to address unmet medical needs in the cardiopulmonary space across the United States.
Products and Services
- AV-101 (Dry Powder Inhaled Imatinib): At the heart of Aerovate Therapeutics' product pipeline lies AV-101, a uniquely formulated dry powder version of imatinib. Designed for inhalation, this innovative therapeutic approach aims at specifically targeting pulmonary arterial hypertension (PAH), a chronic and life-threatening condition characterized by high blood pressure in the lungs' arteries. Currently in a crucial phase of development - Phase 2b/Phase 3 clinical trial - AV-101 represents a beacon of hope for PAH patients seeking alternatives to existing treatments. Its tailored delivery mechanism is anticipated to offer improved efficacy and potentially reduce systemic side effects, marking a significant leap forward in PAH management.
